ACT treats fourth patient in U.S. clinical trial for Stargardt’s Macular Dystrophy
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).